📣 ADDS Atlanta 2026  |  February 23-25. Agenda is Now Available! Register Now!

THERAPEUTIC EXPERTISE

Solutions for Oncology Research

Digital health technologies empower the much-needed transformation of oncology drug development. DHTs can enable more effective trial designs that focus on the patient, improving the patient-centric nature of oncology trials, including immunotherapy treatments such as CAR-T cell therapy and trials investigating associated conditions such as cancer pain and cancer cachexia. 

Schedule a Meeting Read Case Studies
gfx1-Aug-19-2025-06-50-55-7000-PM

Opportunities with Digital Measures

  • Demonstrate meaningful patient-centric benefits
  • Reduce participant burden
  • Expand access to clinical trials
  • Improve the speed and cost-effectiveness of trials 

Indications where DHTs have been used in Clinical Development 

  • Immunotherapy / CAR-T Cell Therapy /
    T-Cell Engager Therapy
  • Cancer Cachexia
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Liver Cancer
  • Blood Cancers
  • Cancer Pain 

Selected Digital Endpoints in Oncology

Physical Activity

  • Moderate to Vigorous Physical Activity (MVPA)
  • Non-Sedentary Time
  • Daily Total Activity Counts
  • Walking (step count, peak cadence, walking speed)

Sleep

  • Total Sleep Time
  • Wake After Sleep Onset (WASO)
  • Sleep Onset Latency
  • Sleep Efficiency

Cardinal Symptoms

  • Cough Frequency
  • Cough Bouts

Vital Signs

  • Heart Rate (HR)
  • Respiratory Rate (RR)
  • Atrial fibrillation (Afib)
  • Oxygen Saturation (SpO2)
  • Blood Pressure
  • Skin Temperature
Physical Activity
  • Moderate to Vigorous Physical Activity (MVPA)
  • Non-Sedentary Time
  • Daily Total Activity Counts
  • Walking (step count, peak cadence, walking speed)
Sleep
  • Total Sleep Time
  • Wake After Sleep Onset (WASO)
  • Sleep Onset Latency
  • Sleep Efficiency
Cardinal Symptoms
  • Cough Frequency
  • Cough Bouts
Vital Signs
  • Heart Rate (HR)
  • Respiratory Rate (RR)
  • Atrial fibrillation (Afib)
  • Oxygen Saturation (SpO2)
  • Blood Pressure
  • Skin Temperature

Digital Endpoint Guide

To learn more about opportunities with wearable digital health technologies in Oncology clinical trials, download our full guide.

Download the Guide

Functional Assessments

Physical functioning and sleep are meaningful to patients’ quality of life and often correlate with improved outcomes. However, traditional assessments of these meaningful aspects of health are episodic and subjective, limiting the insights they can provide.

Demonstrate meaningful patient-centric benefits and make informed, data-based decisions with continuous, quantitative, digital measures of physical activity, mobility, and sleep behavior collected with our state-of-the-art wearable digital health technology solution.

Read Case Study
gfx1@2x

Digital Health Monthly Webinar

Our expert panel share how digital health technologies can enable remote monitoring to detect early signs of CRS, addressing key challenges that limit patient access while preserving patient safety. They review data on the technical feasibility, outline key lessons learned, and discuss next steps to fully realize a CRS monitoring digital health solution.

Immunotherapy-Related Adverse Events

Immunotherapies including CAR-T cell therapy, Bi-specific T-cell engager (BiTE) therapy, and immune checkpoint inhibitors are promising advancements in cancer treatment, but risk of serious adverse events such as cytokine release syndrome (CRS), neurotoxicity, and sepsis lead to prolonged hospital stays that can increase patient burden and trial costs.

Overcome these barriers with our remote patient monitoring platform and AI-powered risk monitoring. Continuous, remote monitoring of patient vital signs can reduce or eliminate prolonged hospitalization to reduce burden and cost while still prioritizing patient safety.

Download the Solution Sheet
033fbdef42f29f2c2de97a35e5e3cd69c94a4408

Patient-Focused Digital Measures Reports

Check out our oncology digital measure reports inspired by the FDA’s Patient-Focused Drug Development (PFDD) initiative’s goal of better incorporating the patient’s voice in drug development and evaluation, and leverages information from their comprehensive collection of Voice of the Patient Reports.

Experience in Oncology Trials

16
trials
2,472
participants
24
countries
495
sites